Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome
August 06 2020 - 5:30PM
Business Wire
Illumina, Inc. (Nasdaq:ILMN). The power to make bigger
discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent
Kit. The new NovaSeq 6000 v1.5 Reagent Kits aim to make whole
genome sequencing more accessible and affordable for labs of all
sizes with the introduction of the $600 genome. By delivering on
key customer requests, and a more attractive price per sample for
all applications, the new kits bring data-rich applications—such as
single cell genomics, whole genome sequencing, and liquid
biopsy—within closer reach to help researchers unlock the full
story of genetic variation and answer their biggest biological
questions.
“In order to explore biology at higher resolution, we rely on
technologies that enable us to dive deeper into previously
unrecognized cell types with single cell and spatial applications,”
said Edwin Hauw, Vice President of Marketing at 10x Genomics.
“Together with Illumina's technologies, we are able to simplify and
amplify our workflows to capture new insights into the inner
workings of biology.”
“As a scientist, I consistently push the limits of my research
and drive innovation with each new discovery,” said Dr. Christopher
Mason. “Illumina’s pioneering technology and leading-edge
advancements help unlock new applications in an accessible way,
giving researchers the ability to concentrate on life-impacting
science, for everything from COVID-19 and infectious disease, to
cancer and epigenetics.”
Coupled with the new NovaSeq 6000 v1.5 Reagent Kit, NovaSeq 6000
can accelerate scientific breakthroughs with tremendous
flexibility, accuracy and scale—delivering unique,
industry-changing capabilities to drive discovery through deep
sequencing, access to data-intensive next generation sequencing
applications, and sequencing of large sample cohorts—now more
affordable than ever.
In addition to the improved per sample sequencing cost, the
NovaSeq 6000 v1.5 Reagent Kits have been enhanced to include the
following key features:
- Improved Quality Specification Score – Manufacturing
enhancements alongside robust formulations provides a new level of
confidence and quality with average Q30 scores of ≥ 85 percent, for
read lengths up to 2x150bp.
- Fully Supported Unique Molecular Identifiers (UMIs) –
Additional cycles per kit enable customers to adopt UMIs for
advanced applications including the detection of rare variants and
transcripts without sacrificing sequencing read length.
- Extended Shelf Life from Three to Six Months –
Enables labs to receive large quantities of reagents at once,
supports efficient planning for future research, and provides
greater flexibility of reagent use.
- Support for New Library Prep Kits and Assays – Fully
supports the new Illumina DNA PCR-Free Prep Kit, providing a
complete whole genome sequencing solution when used in combination
with TruSight Software Suite. The new NovaSeq S4 Reagent Kit v1.5
(35 cycles) provides the optimal read length for various counting
applications, such as gene expression profiling.
“The NovaSeq 6000 v.1.5 Reagent Kit offers accelerated access to
exceptional discovery power and operating efficiency, unlocking
high throughput applications at our best price ever,” said Mark Van
Oene, Chief Commercial Officer of Illumina. “With our customers’
needs top of mind, Illumina reimagined the kit with innovative
solutions that extend the unmatched throughput and high accuracy of
the NovaSeq to fuel more in-depth research across the scientific
spectrum.”
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties, including the expectation for lower costs
related to the storing and managing of genomic data costs. Among
the important factors that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services; (ii) our ability to deploy new products, services, and
applications, and to expand the markets for our technology
platforms; and (iii) the acceptance by customers of our newly
launched products, which may or may not meet our and their
expectations once deployed, together with other factors detailed in
our filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806006031/en/
Investors: Jacquie Ross, CFA 858-255-5243
ir@illumina.com
Media: Dr. Karen Birmingham +44 7500 105665
kbirmingham@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024